Increasing evidence suggests a role for interferons (IFNs) in neurodegeneration.
Introduction
Emerging data suggest that immune dysfunction contributes, not only to the progression, but also to the onset of neurodegenerative diseases including Parkinson's disease (PD) 1 . In this respect, human genetics and functional genomics studies indicate that interferon-mediated signaling pathways, both type I and type II, contribute to brain ageing and human neurodegenerative diseases 2, 3, 4 . With regard to PD, there is evidence for a link between expression network signatures of disease loci and IFN-γ signaling 5 . Recently, IFN-γ response has also been linked to the selective vulnerability of dopaminergic (DA) neurons 6 . IFN-γ is a cytokine primarily produced by T-lymphocytes and natural killer cells as part of the immune response against pathogens 7 . IFN-γ plays a key role in both the innate and adaptive immune responses and contributes to macrophage activation, up-regulation of major histocompatibility complex (MHC), and modulation of T helper response 8 . Besides its role in immune responses against pathogens, IFN-γ is also fundamental to normal brain physiology 9 . The high incidence of postencephalitic parkinsonism following the pandemic influenza towards the end of World War I, had already suggested a selective vulnerability of DA neurons to pathogen-driven immune responses. Indeed, related pathological studies revealed the presence of inflammatory encephalitis in the midbrain and basal ganglia, without central nervous system viral invasion 10 .
Supporting a possible role of IFN-γ in the disease process, increased levels of IFN-γ in the serum, as well as increased production of IFN-γ by peripheral CD4+ T cells, have been detected in PD patients compared to healthy controls 11, 12 . Moreover, a significant co-expression of α -synuclein and IFN-γ has been found within the substantia nigra of PD patients 13 . Experimental models also support this connection, whereby IFN-γ has been linked to selective, progressive, DA neurodegeneration in rodents 11, 14, 15 . More recent studies also point towards the interaction between PDrelated genes and IFN-γ induced DA neuronal loss 16 . The study by Kozina et al. shows that human pathogenic mutations in the leucine rich repeat kinase 2 (LRRK2) gene, the most common genetic cause of familial and sporadic PD 17 , synergizes with lipopolysaccharide (LPS)-induced inflammation to potentiate DA neurodegeneration through IFN-γ-mediated immune responses 16 . Interestingly, LRRK2 is an IFN-γ target gene 18, 19 and its expression is increased in immune cells upon IFN-γ stimulation and exposure to pathogens 18, 20, 21, 22, 23 . Genetic polymorphisms in LRRK2 have also been associated with Crohn's disease (CD) and leprosy 24, 25, 26 , suggesting overlapping pathogenetic mechanisms among chronic inflammatory diseases, infections and PD. LRRK2-PD manifests similar clinical phenotypes to idiopathic PD, displaying a strong age-dependent development of PD symptoms.
Notably, PD patients carrying the LRRK2 G2019S mutation have distinct peripheral inflammatory profiles 27 . Despite the evidence of a link between IFN type II immune response and PD, mechanisms through which IFN-γ contributes to neurodegeneration and interacts with PD genes, such as LRRK2, are still unknown.
Based on these premises, we aimed to investigate mechanisms of IFN-γ-mediated neurotoxicity and to examine the role of the most common pathogenic missense mutation, LRRK2 G2019S, in modulating IFN-γ signaling.
Results

IFN-γ induces LRRK2 expression in human neurons
To examine the impact of IFN type II signaling on human neurons, we employed induced pluripotent stem cell (iPSC)-derived neural precursor cells (NPCs) Control
NPCs were differentiated into neuronal cultures enriched in DA neurons and treated with IFN-γ for 24 hrs. Since previous work has shown that IFN-γ induces LRRK2 in immune cells 18, 20, 21, 22 , we examined LRRK2 mRNA and protein levels in untreated and IFN-γ treated neuronal cultures. IFN-γ stimulation significantly increased LRRK2 mRNA and protein levels in human neurons (Fig. 1A, B ). To evaluate whether LRRK2 missense mutations influence the IFN-γ-driven induction of LRRK2, we used NPC lines derived from patients carrying the LRRK2 G2019S mutation and corresponding isogenic controls 28, 29 . As previously reported 29 , isogenic NPCs were efficiently differentiated into DA neurons without significant differences among patients and controls ( Supplementary Fig. 1A ). LRRK2 protein expression was similar among different lines ( Supplementary Fig. 1B ). IFN-γ treatment also increased LRRK2 protein levels in LRRK2 G2019S PD patient-derived neurons (Fig.   1C ). IFN-γ treatment did not affect neuronal cell viability, as assessed by LDH assay ( Supplementary Fig. 1C ). To examine the specificity of the effects observed with IFN-γ , control neurons were treated with 200 IU/mL IFN-γ, 100 ng/mL LPS or 100 IU/mL IL-1β for 24 hrs and LRRK2 mRNA levels were measured using qRT-PCR. Only IFN-γ efficiently induced LRRK2 expression in human neurons (Fig. 1D ).
LRRK2 G2019S alters IFN-γ signaling in human neurons
To characterize IFN-γ response in human neurons, healthy control NPC lines were differentiated into DA neurons and treated with 200 IU/mL IFN-γ for 24 hrs. IFN-γ-regulated genes, selected according to the INTERFEROME gene expression database (Interferome DB v2.0) 30 , were profiled by qRT-PCR in vehicle-and IFN-γ-treated neurons. Interferon Gamma Receptor 1 (IFNgR1), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), and mitogen-activated protein kinase 14 (MAPK14) were significantly down-regulated (Fig. 1E ), whereas Janus kinase 2 (JAK2), eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2), AKT serine/threonine kinase 3 (AKT3), signal transducer and activator of transcription 1 (STAT1), suppressor of cytokine signaling 1 (SOCS1), intercellular adhesion molecule 1 (ICAM1), and interferon regulatory factor 1 (IRF1) were significantly upregulated in IFN-γ treated compared to vehicle treated neurons (Fig. 1F) . To examine whether LRRK2 G2019S mutation influences neuronal IFN-γ response, we examined the expression of the most significant IFN-γ upregulated genes in LRRK2 G2019S mutant NPC-derived neurons and corresponding isogenic controls. Among the upregulated genes analysed, we found significantly higher mRNA levels of AKT3 in LRRK2 G2019S mutant neurons compared to the corresponding isogenic controls upon IFN-γ stimulation (Fig. 1G) . These results were confirmed in two different pairs of LRRK2 G2019S patient neurons and isogenic gene corrected controls ( Fig. 1H) . At the protein level, we detected a modest non-significant increase of AKT3 in IFN-γ-treated cells (Fig. 1I) . We then examined whether LRRK2 G2019S influences AKT phosphorylation state. Given the lack of phospho-AKT3-specific antibodies, an antibody recognizing all AKT isoforms was used. IFN-γ treatment reduced AKT phosphorylation in both LRRK2 G2019S and control neurons (Fig. 1J) ; however, AKT phosphorylation was significantly reduced in LRRK2 G2019S compared to control neurons upon IFN-γ treatment (Fig 1J, K ).
LRRK2 G2019S reduces nuclear NFAT3 in human neurons
Next, we investigated the possible impact of reduced AKT phosphorylation and reasoned that this could have a negative effect on the translocation and transcriptional activity of the nuclear factor of activated T-cells (NFAT) 31, 32 . First, we employed HEK293 NFAT reporter cell lines. We transfected them with LRRK2 wildtype (wt) or LRRK2 G2019S constructs ( Fig. 2A) , and measured NFAT transcriptional activity in response to phorbol-12-myristate-13-acetate (PMA) and ionomycin. In line with previous reports 33 , we found that overexpression of LRRK2 wt inhibits NFAT-dependent transcriptional activity (Fig. 2B ). Moreover, NFAT activity was decreased to a greater extent in cells overexpressing LRRK2 G2019S (Fig. 2B ).
Next, HEK293 NFAT reporter cells (overexpressing LRRK2 wt or LRRK2 G2019S)
were treated with IFN-γ and stimulated with PMA/ionomycin. IFN-γ treatment decreased NFAT activity and the most potent effect was observed in patient LRRK2
G2019S overexpressing cells (Fig. 2C) . Next, we sought to investigate the link between IFN-γ/LRRK2 and NFAT in DA neurons. We first examined the expression levels of the Ca 2+ dependent NFAT isoforms (NFAT1, NFAT2, NFAT3, and NFAT4) in human iPSC-derived neurons and microglia by qRT-PCR ( Supplementary Fig. 1D ).
As NFAT3 exhibited the highest expression in neurons, we focused on this family member. To further elucidate the link between LRRK2 and NFAT in PD, we transfected LRRK2 G2019S PD neurons and corresponding isogenic controls with an NFAT3-GFP reporter plasmid and examined NFAT localization by quantitative immunofluorescent analysis. Consistent with the luciferase assay data, we observed decreased nuclear NFAT localization in patient LRRK2 G2019S neurons compared to isogenic controls (Fig. 2D, E) . Interestingly, IFN-γ treatment further decreased the nuclear localization of NFAT3 and the most potent effect was observed in patient LRRK2 G2019S neurons (Fig. 2D, F) . To confirm that LRRK2 acts downstream of IFN-γ, we generated LRRK2 knockout (LRRK2 KO) iPSCs ( Supplementary Fig. 1E ).
LRRK2 KO iPSCs and isogenic controls were differentiated into neurons and treated with IFN-γ or vehicle. We observed increased nuclear NFAT localization in LRRK2
KO neurons compared to isogenic controls, whereas IFN-γ did not have a significant impact on NFAT localization in LRRK2 KO neurons (Fig. 2D, G) . We then performed
Western blot analysis for NFAT levels in LRRK2 G2019S PD patient neurons and controls with and without IFN-γ treatment. No changes were observed in total NFAT levels at basal conditions, whereas a significant reduction was observed upon treatment with IFN-γ in both controls and LRRK2 G2019S PD patient neurons ( Supplementary Fig. 1F ). Similar results were obtained with nuclear and cytosolic fractionation experiments ( Supplementary Fig. 1G, H) . Notably, we observed a reduction of NFAT levels upon IFN-γ treatment ( Supplementary Fig. 1F -H). Given that IFN-γ activates the proteasome 34, 35 , we examined whether the reduction of total NFAT levels observed in IFN-γ-treated neurons could be mediated by proteasome activation. To this end, control neurons were treated with IFN-γ with or without proteasome inhibitor, MG132, and total levels of NFAT were assessed by Western blot. Interestingly, proteasome inhibition restored NFAT levels in IFN-γ treated neurons ( Supplementary Fig. 1I ). Taken together, these data indicate that IFN-γ leads to NFAT degradation by the proteasome and that the presence of the mutation G2019S enhances the retention of NFAT in the cytosol by reducing AKT phosphorylation.
LRRK2 alters the ER-related neuronal calcium response to IFN-γ
Since NFAT1-4 family members are regulated by Ca 2+ signaling, we examined LRRK2 G2019S-related changes in Ca 2+ homeostasis. Fura-2 live-cell Ca 2+ imaging was performed in two isogenic pairs and revealed that LRRK2 G2019S PD neurons have higher cytosolic Ca 2+ basal levels compared to isogenic controls (Fig. 3A, B) .
Upon KCl depolarization, LRRK2 G2019S PD neurons showed significantly reduced Ca 2+ influx and longer recovery time compared to controls (Fig. 3A, B (Fig. 3D ). On the other hand, no significant difference was observed in IFN-γ-treated LRRK2 G2019S mutant neurons, confirming a preexisting depletion of ER Ca 2+ -stores (Fig. 3D ).
LRRK2 regulates NFAT shuttling through microtubules
Integrity of the microtubule network is necessary for NFAT translocation and T-cell activation 36 . Furthermore, LRRK2 interacts with and regulates several cytoskeletal components in a variety of cell types 37 . LRRK2 is part of the NRON [noncoding (RNA) repressor of NFAT] complex that also contains IQGAP1 33, 38 , a scaffold protein that, among other functions, regulates cytoskeleton architecture, including actin filaments and microtubules, and coordinates their interactions during cell migration at leading edges 39, 40, 41 . To examine whether IQGAP1 is involved in LRRK2 mediated defects of NFAT shuttling, we knocked down IQGAP1 in HEK293
NFAT reporter cell lines (Fig. 4A, B) . Knockdown of IQGAP1 increased NFAT activity, both at basal condition and upon PMA/Ionomycin stimulation (Fig. 4C, D) . 
IFN-γ impairs neurite outgrowth in human iPSC-derived neurons
We next sought to investigate whether the reduction of NFAT3 nuclear localization observed in LRRK2 G2019S PD patient neurons has functional consequences relevant to human disease. Given that NFAT signaling is essential for axonal outgrowth in response to neurotrophins and netrins 42 , and LRRK2 has been implicated in neurite outgrowth defects 29, 43, 44 , we examined whether NFAT signaling could play a role in LRRK2-mediated defects of neurite outgrowth. To this end, three isogenic pairs of LRRK2 G2019S PD neurons and corresponding controls were treated with MCV1, a potent specific inhibitor of calcineurinmediated NFAT activation, or IFN-γ, and neurite length was quantified by immunostaining for β -Tubulin III. NFAT inhibition, as well as IFN-γ treatment, led to a significant decrease of neurite length in both control and LRRK2 PD iPSCderived neurons (Fig. 5A, B) . The effect of IFN-γ on neurite length was confirmed by immunostaining for TH (Supplementary Fig. 2A G2019S microglia compared to control (Fig. 6D ). However, IFN-γ significantly decreased motility of G2019S, but not control, microglia (Fig. 6D ). Immunostaining analysis of NFAT1 subcellular localization revealed increased levels of nuclear NFAT in LRRK2 KO microglia treated with ionomycin ( Supplementary Fig. 4A , B). On the contrary, nuclear NFAT levels were significantly reduced in LRRK2 G2019S microglia ( Supplementary Fig. 4A , B). We next examined the functional consequences of NFAT activity in human microglia. Given that ionomycin is a weak stimulator of cytokine release in microglia, we employed LPS stimulation to induce NFAT nuclear shuttling, based on previous reports 47 . Nuclear NFAT1 was significantly increased in LRRK2 KO compared to CTRL microglia upon LPS treatment, whereas a significant reduction was observed in LPS-stimulated LRRK2
G2019S cells compared to isogenic controls ( Supplementary Fig. 4A , C). Next, control, G2019S and LRRK2 KO iPSC-derived microglia were treated with LPS and cytokine production was assessed by Multiplex Elisa ( and production of IL-1β was assessed by Elisa. Levels of IL-1β were significanty decreased in poly(I:C)-stimulated LRRK2 KO microglia compared to CTRL microglia.
Poly(I:C)-treated LRRK2 G2019S microglia showed an increase in IL-1β production compared to isogenic controls, although this increase was not significant (Fig. 6G) .
Finally, to study the effects of microglia on neurons, iPSC-derived neurons were exposed to conditioned media from LPS-activated microglia (microglial-conditioned media -MCM-). The findings showed that only MCM from LRRK2 G2019S activated microglia contributes to an inflammatory/toxic environment that affects neurite elongation ( Fig. 6H and Supplementary Fig. 5B ).
Discussion
Our study provides further understanding of the role of IFN type II signaling in PD and shows that LRRK2 G2019S mutation synergizes with IFN-γ, thus, serving as a potential direct link between inflammation and neurodegeneration in PD.
Besides 54 . We found that IFN-γ reduces AKT phosphorylation in human neurons. Interestingly, IFN-γ treatment also suppresses AKT signaling in human macrophages, supporting the evidence that neuronal IFN-γ signaling is similar to that of immune cells 55 . Previous work has implicated LRRK2 in AKT phosphorylation and shown that disease associated mutations reduce its interaction with and phosphorylation of AKT 56, 57, 58 . In line with these findings, we found that IFN-γ synergizes with LRRK2 G2019S mutation to suppress AKT phosphorylation. Given the role of AKT in the regulation of NFAT activity 31, 32 , we explored the impact of IFN-γ on NFAT signaling and its possible negative regulation of NFAT along with LRRK2 33 . In support of the study of Liu et al. 33 , we found that LRRK2 is a negative regulator of NFAT activity in a variety of human cell types, including HEK293, human macrophages as well as iPSC-derived neurons and microglia. Furthermore, we have identified a role for IFN-γ as negative regulator of NFAT. This effect was mediated by the IFN-γ-dependent induction of LRRK2 levels that acts as a negative regulator of NFAT. On the other side, IFN-γ-dependent activation of the proteasome 34, 35 leads to degradation of NFAT. It is likely that the activation of the proteasome is mediated by the increased levels of SOCS1, one of the induced IFN-γ target genes, that activates the ubiquitin-proteasome pathway 59 .
Importantly, LRRK2 G2019S mutation results in even more pronounced effects on NFAT activity, due to its negative impact on AKT phosphorylation that in turn impairs NFAT translocation 31, 32 .
In Finally, we have identified cell-type specific effects of reduced NFAT translocation.
Consistent with the role of calcineurin/NFAT signaling in the regulation of axon outgrowth 42 , we show that NFAT signaling plays a role in neurite outgrowth in human neurons and that IFN-γ synergizes with LRRK2 G2019S to inhibit NFAT activity and determine a reduction of neurite length. Therefore, our results provide further mechanistic explanation of the neurite growth defects that have been observed in LRRK2 G2019S neurons. To examine the cell-specific role of reduced NFAT activity, we have employed human macrophages and human iPSC-derived microglia.
Whether adult microglia express LRRK2 is still controversial; our data show that LRRK2 is expressed by human microglia at basal conditions and its expression is enhanced by IFN-γ. In addition, we show that human microglia produce IFN-γ when stimulated by LPS. However, we cannot exclude that the in vitro culture conditions used in the present study enhance LRRK2 expression and cytokine production. In line with its role in cytoskeletal remodeling 63 , IFN-γ stimulation reduced the motility of microglia. However, such an effect was significant only in LRRK2 G2019S microglia, suggesting that PD LRRK2 mutations enhance immune responses to IFN-γ.
Importantly, we show that LRRK2 deficiency in innate immune cells leads to increased NFAT nuclear localization. On the contrary, LRRK2 G2019S was associated to decreased nuclear NFAT. Upon stimulation with LPS, which is known to promote NFAT nuclear translocation in microglia 47 , we detected LRRK2-and NFAT-dependent changes in cytokine production. Specifically, IL-6, TNF-α, IL-8, and MCP-1 production was decreased in G2019S microglia with opposite changes in LRRK2 KO microglia. However, G2019S microglia showed increased production of IL-10, IL-1β, IL-12p70 and MIP-1β upon stimulation, suggesting that additional mechanisms other than NFAT regulate cytokine responses in LRRK2 KO and G2019S microglia. In this respect, we show that LRRK2 modulates microglia activation by interfering with the metabolic switch toward glycolysis that normally occurs in LPS-activated macrophages 64 . Importantly, activated G2019S microglia leads to neurite shortening, suggesting a neurotoxic effect of LRRK2-driven immunological changes in PD.
Increased IFN-γ levels have been documented in PD patients 11, 12 . The source of IFN-γ in the aged and PD brain still needs to be identified. Our work shows that In summary, our work shows that LRRK2 G2019S sensitizes neurons to IFN-γ inflammatory responses, thus serving as a potential direct link between inflammation and neurodegeneration in PD. We have uncovered a cell type-specific role for the synergistic effect between IFN-γ and LRRK2 that may influence PD risk through specific ageing signatures that converge on the immune system. Importantly, given the role of LRRK2 in sporadic PD 69, 70 , the relevance of our work goes beyond LRRK2 G2019S patients and suggests that the IFN-γ/LRRK2 axis may be a potential target for intervention in acute or chronic states of neuroinflammation in genetic and sporadic PD.
Methods
Differentiation of NPCs into midbrain DA neurons
All cells used in the study were derived from patients who signed an informed consent 29 . The Ethics Committee of the Medical Faculty and the University Hospital
Tübingen (Ethikkommission der Medizinischen Fakultät am Universitätsklinikum
Tübingen) approved the protocol before performing the experiments. Patient LRRK2 G2019S and corresponding gene-corrected isogenic control iPSC-derived NPCs were previously generated using an NPC-based protocol 28 . NPC differentiation into 
Generation of LRRK2 knock out iPSCs
LRRK2 KO iPSCs (clone #1) was generated using zinc finger nucleases ZFNs 
Experiments with microglia-conditioned medium (MCM)
The conditioned medium was collected after 24 hours from control microglia or 100 ng/mL LPS-activated microglia. MCM was then filtered, diluted 1:1 with neuronal medium and applied to neurons. Cells were fixed after 48 hrs and used for neurite length assay.
THP-1 experiments
Human THP-1 cell lines were purchased from Sigma Aldrich and cultured in RPMI 1640 (Life technologies), 2mM Glutamax, and 10% FBS. THP-1 cells were differentiated into macrophages with 25 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma) for 48 hrs. For LRRK2 knockdown experiments, the following high titer lentiviruses were purchased from Sigma Mission Library: TRCN0000021462 10^8 TU vector pLK0.1, TRCN0000021460 10^8 TU vector pLK0.1, and SHC002V non-target control. Lentiviral infection of THP-1 macrophages was performed with spinfection at MOI 10.
Plasmids
The plasmids SF-tagged LRRK2 wt and SF-tagged LRRK2 G2019S were a kind gift from CJ Gloeckner. pEGFP-C1 NFAT3 was purchased from Addgene (Cat.
No.10961). 
Luciferase assay
Statistical analysis
The Statistical Package GraphPad Prism version 7.00 (GraphPad Software, San Diego California USA) was used to analyse the data. Statistical testing involved two- 
